45 results about "Submucosa" patented technology

The invention belongs to the technical field of medical equipment. The endoscopic surgery operation quality real-time quantitative evaluation system comprises an endoscopic camera probe used for collecting endoscopic images and an endoscopic handle used for operation. The displacement sensor is integrated on the endoscope camera probe and is used for detecting the endoscope entering speed; the pressure sensor is integrated on the gas injection pipeline and is used for detecting the intracavity pressure; the force sensor is integrated on the endoscope handle and is used for detecting the tissue traction deformation; the optical coherence layer scanning probe is integrated on the endoscope camera probe and used for detecting the thickness of the submucous membrane, and the processing terminal is used for conducting real-time quantitative evaluation on the endoscopic surgery operation quality according to the endoscope entering speed, the intracavity pressure, the thickness of the submucous membrane, the tissue traction deformation image, the included angle between an instrument and a focus normal and the complication response time. According to the invention, full-process datamation real-time accurate evaluation of operation skills and operation safety of operators is realized.

Apparatuses, systems and methods are provided for treating pulmonary tissues via delivery of energy, generally characterized by high voltage pulses, to target tissue using a pulmonary tissue modification system (e.g., an energy delivery catheter system). Example pulmonary tissues include, without limitation, those within the respiratory tract, particularly the epithelium (the goblet cells, ciliated pseudostratified columnar epithelial cells, and basal cells), lamina propria, submucosa, submucosal glands, basement membrane, smooth muscle, cartilage, nerves, pathogens resident near or within the tissue, or a combination of any of these. The systems may be used to treat pathogens, such as bacteria and viruses, particularly coronaviruses.

Apparatuses, systems and methods are provided for treating pulmonary tissues via delivery of energy, generally characterized by high voltage pulses, to target tissue using a pulmonary tissue modification system (e.g., an energy delivery catheter system). Example pulmonary tissues include, without cells), lamina propria, submucosa, submucosal glands, basement membrane, smooth muscle, cartilage, nerves, pathogens resident near or within the tissue, or a combination of any of these. The system may be used to treat a variety of pulmonary diseases or disorders such as or associated with COPD (e.g., chronic bronchitis, emphysema), asthma, interstitial pulmonary fibrosis, cystic fibrosis, bronchiectasis, primary ciliary dyskinesia (PCD), acute bronchitis and / or other pulmonary diseases or disorders.

Methods are disclosed for dissecting a mucosa and a submucosa from a muscularis propria from a region of an organ of a subject, wherein the organ is not the esophagus. In some embodiments, the organ is in the gastrointestinal tract. These methods include injecting submucosally into the organ of the subject a pharmaceutical composition comprising an extracellular matrix (ECM) hydrogel to form a cushion between the submucosa and the underlying muscularis propria at the region of the organ, wherein the ECM hydrogel has the following characteristics: a) a time to 50% gelation of less than 30 minutes at a temperature of about 37° C.; b) a flow viscosity suitable for infusion into the organ; and c) a stiffness of about 10 to about 400 Pascal (Pa).

Ingestible devices can directly deliver therapeutic agents to desired tissue(s) of the GI tract of a subject, such as the submucosa, the mucosa, and / or the mucus layer of the GI tract, and methods of using the same. The ingestible devices can deliver therapeutic agents in a safe, effective, and reliable manner. The disclosure also provides pharmaceutical compositions for use in methods of treating a disease or condition.

The present invention relates to an artificial digestive tract tissue for training in endoscopic submucosal dissection (ESD) and a method for manufacturing the same. Specifically, the invention relates to an artificial digestive tract tissue configured to mimic the mucosal layer, submucosal layer, and muscle layer constituting the human digestive tract tissue in a multilayer structure, such that swelling occurs upon liquid injection and a color change occurs due to changes in salt concentration, and to a casting and curing-based hydrogel molding process for manufacturing the same. According to the present invention, the problems associated with existing animal tissue-based ESD training simulators can be resolved, repeated use is possible, and training tailored to the structural characteristics of specific organs (stomach, large intestine, small intestine, etc.) is possible.

Methods are disclosed for dissecting a mucosa and a submucosa from a muscularis propria from a region of an organ of a subject, wherein the organ is not the esophagus. In some embodiments, the organ is in the gastrointestinal tract. These methods include injecting submucosally into the organ of the subject a pharmaceutical composition comprising an extracellular matrix (ECM) hydrogel to form a cushion between the submucosa and the underlying muscularis propria at the region of the organ, wherein the ECM hydrogel has the following characteristics: a) a time to 50% gelation of less than 30 minutes at a temperature of about 37° C.; b) a flow viscosity suitable for infusion into the organ; and c) a stiffness of about 10 to about 400 Pascal (Pa).

Apparatuses, systems and methods are provided for treating pulmonary tissues via delivery of energy, generally characterized by high voltage pulses, to target tissue using a pulmonary tissue modification system (e.g., an energy delivery catheter system). Example pulmonary tissues include, without limitation, the epithelium (the goblet cells, ciliated pseudostratified columnar epithelial cells, and basal cells), lamina propria, submucosa, submucosal glands, basement membrane, smooth muscle, cartilage, nerves, pathogens resident near or within the tissue, or a combination of any of these. The system may be used to treat a variety of pulmonary diseases or disorders such as or associated with COPD (e.g., chronic bronchitis, emphysema), asthma, interstitial pulmonary fibrosis, cystic fibrosis, bronchiectasis, primary ciliary dyskinesia (PCD), acute bronchitis and / or other pulmonary diseases or disorders.

The utility model relates to the technical field of medical balloons, in particular to a balloon device which comprises a catheter seat, a flexible catheter, a fixing ring and a balloon. One end of the flexible catheter is communicated with the catheter seat, the other end of the flexible catheter is fixedly connected with the fixing ring, the balloon is arranged on the side, away from the flexible catheter, of the fixing ring, and the flexible catheter is communicated with the balloon through a through hole in the fixing ring. Part of the balloon is attached to the circumferential contour of the fixing ring to form a connecting part, the balloon is fixedly connected with the fixing ring through the connecting part, and the balloon forms an expanding structure extending in the axial direction of the fixing ring after being expanded. In order to solve the technical problem that an existing ESD operation has defects, according to the balloon device, a catheter base is communicated with an external gas-liquid source, gas or liquid can be injected into a balloon through the catheter base so that the balloon can be filled, the filled balloon can eject pathological upper-layer mucous membrane tissue open, the lower layer of the mucous membrane can be exposed, and therefore the balloon device can be used for protecting the upper layer of the mucous membrane. Therefore, a doctor can conveniently perform stripping.

Disclosed in the present disclosure are a chitosan-based temperature-sensitive endoscopic submucosal injection, and a preparation method therefor and use thereof. The injection comprises chitosan suitable for conventional pH value, polyvinylpyrrolidone, sodium β-glycerophosphate, and sodium bicarbonate. The injection has good low-temperature stability and high injectability, and can be injected by means of utilizing a conventional endoscopic injection needle currently in clinical use. Meanwhile, after being injected into the submucosa, the injection can rapidly form a hydrogel with relatively high mechanical strength higher-strength hydrogel under the action of body temperature, and exhibits higher tissue adhesion, which enables more stable support for the elevated state of the mucosal layer, thereby delaying the height decrease, better facilitating ESD operation, and reducing the occurrence probability of complications. Therefore, the injection holds significant practical value in clinical applications.

The invention relates to the field of allergic rhinitis, and discloses an application of sodium hyaluronate in preparation of an external medicine for treating allergic rhinitis. Based on actual clinical efficacy verification, the mechanism of sodium hyaluronate playing efficacy is that sodium hyaluronate can be used for preparing an external medicine for treating allergic rhinitis; sodium hyaluronate is used for reducing drainage lymph nodes in an atopic individual area and generating specificity I gE by nasal submucosa plasma cells, blocking contact between allergens and the surface specificity I gE of sensitized mast cells or sensitized basophilic granulocytes in a sensitized body, stopping development of anaphylaxis and promoting subduing of nasal mucosa inflammation, so that allergy symptoms are eliminated, and the nasal mucosa inflammation eliminating effect is achieved. According to the embodiment of the invention, the result of treating AR by adopting HA nasal drops shows that an obvious effect is achieved 1-2 days after the medicine is taken, the medicine takes effect quickly, the safety is relatively high, and the medicine can be used as a new product for industrial reproducible production.

Ingestible devices can directly deliver therapeutic agents to desired tissue(s) of the GI tract of a subject, such as the submucosa, the mucosa, and / or the mucus layer of the GI tract, and methods of using the same. The ingestible devices can deliver therapeutic agents in a safe, effective, and reliable manner. The disclosure also provides pharmaceutical compositions for use in methods of treating a disease or condition in a subject in need thereof.

Ingestible devices can deliver therapeutic agents directly to desired tissues of a subject's GI tract, such as the submucosa, mucosa, and / or mucus layer of the GI tract, and methods of using the same. Ingestible devices can deliver therapeutic agents in a safe, effective, and reliable manner. The present disclosure also provides pharmaceutical compositions for use in methods of treating a disease or condition in a subject in need thereof.

The present invention relates to ingestible devices for delivery of therapeutic agents to the gastrointestinal tract. The ingestible device may deliver a therapeutic agent directly to a desired tissue of the GI tract of a subject, such as a submucosal, mucosal, and / or mucous layer of the GI tract, and methods of using the same. The ingestible device can deliver the therapeutic agent in a safe, efficient and reliable manner. The disclosure also provides a pharmaceutical composition for use in a method of treating a disease or condition in a subject in need thereof.

The invention provides a sodium ion-sensitive digestive tract submucosa injection filler and application thereof. The filler comprises a calcium ion complexing cosolvent, gellan gum, a thickening agent, an osmotic pressure regulator and a pH regulator. By utilizing the characteristic that gellan gum and sodium ions are combined to form gel, the tissue filling material is prepared, the tissue filling material reacts with sodium ions in tissue fluid to form gel after being injected into human tissues, the effects of filling and forming bulges are achieved, and auxiliary substances are specifically added to form a stable and effective filling agent without damage to the body.

This application discloses a multi-point submucosal thickness measurement method for endoscopic submucosal dissection (ESD). The method comprises the following steps: image acquisition: obtaining a pathological image obtained by endoscopic submucosal dissection; image preprocessing: enhancing the brightness and highlight contrast of the pathological image and smoothing the pathological image using Gaussian filtering; image feature extraction: extracting texture features from the pathological image using the local binary pattern (LBP) algorithm and generating a vertical coordinate feature map of the same size as the pathological image; feature fusion: superimposing the denoised image, texture feature image, and vertical coordinate feature map obtained from the preprocessing; submucosal pathological tissue segmentation: training the superimposed image using a UNet neural network for image segmentation; multi-point thickness calculation; and quality assessment. This application measures submucosal thickness using pathological tissue images, facilitating the assessment of ESD efficacy and surgical quality control.

To provide methods for dissecting a mucosa and a submucosa from a muscularis propria from a region of an organ of a subject.SOLUTION: Methods are disclosed for dissecting a mucosa and a submucosa from a muscularis propria from a region of an organ of a subject, wherein the organ is not the esophagus. In some embodiments, the organ is in the gastrointestinal tract. These methods include injecting submucosally into the organ of the subject a pharmaceutical composition comprising an extracellular matrix (ECM) hydrogel to form a cushion between the submucosa and the underlying muscularis propria at the region of the organ, wherein the ECM hydrogel has the following characteristics: a) a time to 50% gelation of less than 30 minutes at a temperature of about 37°C; b) a flow viscosity suitable for infusion into the organ; and c) a stiffness of about 10 to about 400 Pascal (Pa).SELECTED DRAWING: None

A method for preparing a thermosensitive submucosal injection for endoscopic submucosal dissection (ESD), relating to the technical field of regenerative medicine. The specific method involves constructing a novel thermosensitive submucosal injection solution capable of sustained-release hemostatic drugs and growth factors using high-pH chitosan, polyvinylpyrrolidone, calcium ions, and disodium β-glycerophosphate. This injection has very low viscosity, does not require special injection devices, is able to be injected using conventional endoscopic injection needles currently used in clinical practice, and exhibits high injection rate. Additionally, after being injected into the submucosal layer, this injection rapidly forms a high-strength hydrogel under body temperature, more stably supporting the raised state of the mucosal layer to facilitate ESD operations. It also reduces intraoperative and postoperative bleeding, promotes postoperative wound healing, and holds significant clinical practical application value.

The aim of the invention is to provide a traction device for sufficiently exposing the submucosa so as to provide suitable conditions for the dissection device to move freely throughout the entire dissection of the tumoral mucosa. The traction device (1) of the invention is characterised in that it comprises a proximal anchor (3) that is mounted so as to move relative to an elastic member (2) between a minimum proximal distance and a maximum proximal distance, and in that the traction device comprises an adjustment member (6) configured to adjust the maximum proximal distance between the initial maximum proximal distance and a final maximum proximal distance smaller than the initial maximum proximal distance.

The invention discloses an absorbable anti-inflammatory catgut suture and a manufacturing method thereof, and belongs to the technical field of biomedical materials. The catgut suture is prepared from a catgut submucous membrane as a raw material through the steps of cleaning and bulking, degreasing, submucous membrane stripping, decellularization treatment, winding, dehydration and shaping and the like. An enzyme treatment step is introduced in a decellularization treatment stage, so that the immunogenicity of the material is remarkably reduced, and the catgut is endowed with an active anti-inflammatory characteristic. The catgut suture prepared by the method is few in cell residue, complete in collagen structure, appropriate in mechanical strength, light in inflammatory response after being implanted in vivo, high in wound healing speed, excellent in biocompatibility and suitable for various surgical suturing.

The present invention relates to the technical field of image processing, and specifically relates to a redness differentiation calibration (RDC) method for a medical image, the method comprising the following steps: acquiring an original image, and obtaining values L, a and b of the original image; performing redness intensity estimation on the original image by means of the values a and b; performing edge information extraction on the original image by means of the value L; calibrating the original image by means of calculation, so as to obtain a calibration result LQ; and using the obtained LQ and the obtained values a and b to convert a CIELAB color space of the original image into an RGB color space, and outputting a result image. Compared with a conventional method, the present technical solution can effectively estimate the redness intensity, calibrates a mucosal structure and tissue features, and highlights microvessels in a superficial mucosa and a submucosa in an endoscope image; moreover, transformation on a non-red area is less, such that a processed image is more suitable for a doctor to observe and make a diagnosis.

The invention discloses a high-frequency incision device with an injection pressure adjusting function, and relates to the technical field of high-frequency incision devices.The high-frequency incision device comprises a core rod, a sliding assembly, a liquid conveying assembly, a liquid guiding assembly and a cutting assembly, the core rod and the sliding assembly are in sliding connection, the core rod and the liquid conveying assembly are in fastening connection, and the liquid guiding assembly and the liquid conveying assembly are in fastening connection; the liquid guide assembly is in fastening connection with the sliding assembly, and the liquid guide assembly is in fastening connection with the cutting assembly. According to the high-frequency incision device, liquid can be injected into the submucous membrane, the mucous membrane is raised, the injection pressure of the high-frequency incision device is adjusted by controlling the instantaneous flow of injection flowing into the pressure tube, the injection efficiency is improved, mucous membrane tissue can be subjected to electrocoagulation marking, the mucous membrane tissue can be cut off, and wounds and bleeding of the upper mucous membrane can be flushed; during flushing, the pressure of bubbles in the flushing liquid is larger than the external atmospheric pressure, so that the bubbles are broken, the flushed flushing liquid is diffused, the flushing range is enlarged, and the flushing efficiency is improved.

An endoscopic tool for facilitating injection of fluid into a tissue submucosa includes a first cannula, a suction source, a fluid lumen, and a second cannula. The first cannula has a suction surface disposed at a distal end and defines a suction lumen. The suction source is coupled to the first cannula and generates a negative pressure within the suction lumen. The second cannula is disposed in a fluid lumen separate from the aspiration lumen, is adapted to be coupled to a fluid source, and carries a needle at a distal end thereof. The tool draws the mucosal layer via aspiration, which expands the submucosal layer and injects fluid via the needle to the expanded portion of the submucosal layer, resulting in an elevated tissue portion around the injection site.

A transanal hemorrhoid treatment system comprising: (a) a sacrorectopexy unit comprising a proctoscope having a tubular body, a side access window, and a light source port, the proctoscope being configured for insertion into the rectum and allowing the targeted application of presacral fixation sutures by a curved suturing needle, the sutures being anchored to the sacral fascia to fix the inner rectal wall and reduce rectal prolapse; (b) a suture rectopexy unit operable by the same or an interchangeable proctoscope, the unit comprising a suture guide adapted to place a series of overlapping sutures in a circular pattern through the rectal mucosa, submucosa, and a partial layer of rectal muscle, approximately 4 cm proximal to the dentate line, so as to fix the mucosa to the underlying muscle to occlude afferent branches of the superior rectal artery; and (c) a mucopexy unit comprising a butterfly-shaped proctoscope for radial expansion and a suture applicator configured to apply single U-shaped sutures to anatomically prominent hemorrhoidal locations above the dentate line, including but not limited to the 3, 7, and 11 o'clock positions, thereby reducing prolapsed hemorrhoidal tissue without excision.

The invention relates to a mucous membrane uplift agent for submucosal separation as well as a preparation method and application thereof. The mucous membrane uplift agent contains a gelatinizing agent, recombinant collagen and poloxamer. The mucous membrane uplift agent provided by the invention is a liquid with relatively low viscosity at room temperature, is beneficial to injection and has a temperature-sensitive phase change effect, and after the mucous membrane uplift agent is injected under the mucous membrane of an affected part of a patient, a liquid injection substance is quickly converted into a gel state under the influence of temperature, and the fluidity is reduced, so that the accumulation of the uplift agent is facilitated, and the uplift height of the mucous membrane is increased; and a safer operation space is created for the digestive tract mucosa dissection operation. The mucous membrane protuberance agent has degradability, so that the wound surface after the diseased mucous membrane is cut off can not be additionally treated, and the residual gel can be degraded or fall off after a certain period of time; meanwhile, the formed gel has a certain wound surface protection capability before falling off or degradation, and can provide protection for the wound surface within a certain time.

Ingestible devices can directly deliver therapeutic agents to desired tissue(s) of the GI tract of a subject, such as the submucosa, the mucosa, and / or the mucus layer of the GI tract, and methods of using the same. The ingestible devices can deliver therapeutic agents in a safe, effective, and reliable manner. The disclosure also provides pharmaceutical compositions for use in methods of treating a disease or condition in a subject in need thereof.

The application discloses absorbable anti-inflammatory catgut and a manufacturing method thereof, and belongs to the technical field of biomedical materials. The catgut is prepared from a sheep intestinal submucosa, and is prepared through the steps of cleaning and swelling, degreasing, submucosa stripping, decellularization, winding and dehydration shaping. An enzyme treatment step is introduced in the decellularization step, which significantly reduces the immunogenicity of the material and endows the catgut with active anti-inflammatory properties. The catgut prepared by the method has less cell residues, complete collagen structure, appropriate mechanical strength, slight inflammatory reaction after being implanted into a body, fast wound healing speed and excellent biocompatibility, and is suitable for suture of various surgical operations.

The application provides a polyurethane / small intestinal submucosa composite material and a preparation method and application thereof, and belongs to the field of medicines. The polyurethane / small intestinal submucosa composite material with an asymmetric structure is prepared by using a freeze-drying and impregnation drying method and different structural forms of the same components. The composite material is porous sponge on one side and dense film on the other side, can effectively prevent leakage on the basis of guaranteeing mechanical properties, and performs full-layer repair. The composite material can adjust the component ratio according to different requirements, and then adjust the mechanical properties, so as to match the normal bladder mechanical behavior of different species. The preparation method of the composite material is simple and convenient, has high popularization, can be popularized to other polyurethane / extracellular matrix materials, and has a good application prospect.

Methods are disclosed for dissecting a mucosa and a submucosa from a muscularis propria from a region of the esophagus of a subject. These methods include injecting submucosally into the region of the esophagus of the subject a pharmaceutical composition comprising a urinary bladder extracellular matrix (ECM) hydrogel, to form a cushion between the submucosa and the underlying muscularis propria at the region of the esophagus, wherein the ECM hydrogel has the following characteristics: a) a time to 50% gelation of less than 20 minutes at a temperature of about 37° C.; b) a flow viscosity suitable for infusion into the esophagus; and c) a stiffness of about 10 to about 400 Pascal (Pa).